Value investing is always a very popular strategy, and for good reason. After all, who doesn’t want to find stocks that have low PEs, solid outlooks, and decent dividends?
Fortunately for investors looking for this combination, we have identified a strong candidate which may be an impressive value; Aperam S.A. (APEMY - Free Report) .
Aperam in Focus
APEMY may be an interesting play thanks to its forward PE of 9.9, its P/S ratio of 0.5, and its decent dividend yield of 4.8%. These factors suggest that Aperam is a pretty good value pick, as investors have to pay a relatively low level for each dollar of earnings, and that APEMY has decent revenue metrics to back up its earnings.
Aperam PS Ratio (TTM)
But before you think that Aperam is just a pure value play, it is important to note that it has been seeing solid activity on the earnings estimate front as well. For current year earnings, the consensus has gone up by 7.4% in the past 30 days, thanks to one upward revision in the past one month compared to none lower.
This estimate strength is actually enough to push APEMY to a Zacks Rank #1 (Strong Buy), suggesting it is poised to outperform. You can see the complete list of today’s Zacks #1 Rank stocks here.
So really, Aperam is looking great from a number of angles thanks to its PE below 20, a P/S ratio below one, and a strong Zacks Rank, meaning that this company could be a great choice for value investors at this time.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year?
From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 – 2017, they soared far above the market's +126.3%, reaching +181.9%.
This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.
See Stocks Today >>